New drug cocktail aims to wipe out breast cancer before surgery

NCT ID NCT04886531

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tests whether giving a combination of three drugs (neratinib, an aromatase inhibitor, and trastuzumab) for 24 weeks before surgery can eliminate all signs of cancer in the breast tissue of people with ER-positive, HER2-positive breast cancer. About 30 postmenopausal women will take part. After surgery, they will receive standard treatments to keep the cancer under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Penn State Cancer Institute

    RECRUITING

    Hershey, Pennsylvania, 17033, United States

    Contact Email: •••••@•••••

    Contact

  • University of Illinois Cancer Center

    RECRUITING

    Chicago, Illinois, 60612, United States

    Contact

  • University of Rochester Medical Center

    RECRUITING

    Rochester, New York, 14642, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53705, United States

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.